Search Result

Results for "

NRP1-a1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Complement System (9) Microtubule/Tubulin (1) Reference Standards (1) VEGFR (3)
By Research Areas:	Cancer (9) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10799

EG00229 trifluoroacetate Maximum Cited Publications 11 Publications Verification	Complement System	Cancer
EG00229 is a *neuropilin 1 (NRP1) receptor* antagonist. EG00229 selectively inhibits VEGF-A binding to *NRP1* b1 domain with an IC₅₀ of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .

HY-112151

EG01377 5 Publications Verification	Complement System	Cancer
EG01377 is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a K_d of 1.32 μM, and IC₅₀s of both 609 nM for *NRP1-a1* and *NRP1-b1*. EG01377 has antiangiogenic, antimigratory, and antitumor effects .

HY-112151A

EG01377 dihydrochloride 5 Publications Verification	Complement System	Cancer
EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a K_d of 1.32 μM, and IC₅₀s of 609 nM for both *NRP1-a1* and *NRP1-b1*. EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects .

HY-133034

*NRP1 antagonist 1*	Complement System	Cancer
NRP1 antagonist 1 (compound 12a) is a potent *NRP1* antagonist with an IC₅₀ of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research .

HY-P10097

Flt2-11	VEGFR	Others
Flt2-11 is a anti-angiogenic peptide, and specifically binds NRP-1. Flt2-11 inhibits NRP-1/sVEGFR-1 interaction.

HY-147762

NRP1 antagonist 2	Complement System	Cancer
NRP1 antagonist 2 (Compound 1) is an *NRP1* antagonist .

HY-163062

Tubulin/NRP1-IN-1	Microtubule/Tubulin Apoptosis Complement System	Cancer
Tubulin/NRP1-IN-1 (compound TN-2) is a dual inhibitor of Tubulin and *NRP1* with IC₅₀s of 0.71 and 0.85 μM, respectively. Tubulin/NRP1-IN-1 significantly inhibits the viability of prostate tumor cell lines and induces apoptosis .

HY-P11647A

RPARPAR acetate	Complement System	Cancer
RPARPAR acetate is a CendR tumor-penetrating peptide. RPARPAR acetate directly binds to the *NRP-1* and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR acetate serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR acetate is applicable in research on tumor targeting and drug delivery .

HY-P11647

RPARPAR	Complement System	Cancer
RPARPAR is a CendR tumor-penetrating peptide. RPARPAR directly binds to the *NRP-1* and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR is applicable in research on tumor targeting and drug delivery .

HY-10799R

EG00229 trifluoroacetate (Standard)	Reference Standards Complement System	Cancer
EG00229 trifluoroacetate (Standard) is the analytical standard of EG00229 (trifluoroacetate) (HY-10799). This product is intended for research and analytical applications. EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC₅₀ of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .

HY-179350A

EG01449	VEGFR	Neurological Disease
EG01449 is a quinoline-based antagonist of Neuropilin-1 (NRP1) with an K_d of 0.6 µM. EG01449 competitively inhibits the binding of VEGFA to NRP1 with an IC₅₀ of 362 nM. EG01449 prevents VEGFA-induced pain by inhibiting *NRP1*-dependent signaling and reducing sodium currents in sensory neurons. EG01449 can be used for the research of nociceptive pain .

HY-179350

EG01449 Free acid	VEGFR	Neurological Disease
EG01449 Free acid is a quinoline-based antagonist of Neuropilin-1 (NRP1) with an K_d of 0.6 µM. EG01449 Free acid competitively inhibits the binding of VEGFA to NRP1 with an IC₅₀ of 362 nM. EG01449 Free acid prevents VEGFA-induced pain by inhibiting *NRP1*-dependent signaling and reducing sodium currents in sensory neurons. EG01449 Free acid can be used for the research of nociceptive pain .

Cat. No.	Product Name	Target	Research Area

HY-P10097

Flt2-11	VEGFR	Others
Flt2-11 is a anti-angiogenic peptide, and specifically binds NRP-1. Flt2-11 inhibits NRP-1/sVEGFR-1 interaction.

HY-P11647A

RPARPAR acetate	Complement System	Cancer
RPARPAR acetate is a CendR tumor-penetrating peptide. RPARPAR acetate directly binds to the *NRP-1* and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR acetate serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR acetate is applicable in research on tumor targeting and drug delivery .

HY-P11647

RPARPAR	Complement System	Cancer
RPARPAR is a CendR tumor-penetrating peptide. RPARPAR directly binds to the *NRP-1* and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR is applicable in research on tumor targeting and drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.